Lantern Pharma announced that the FDA has granted fast track designation for investigational drug candidate, LP-184, for treatment of Glioblastoma. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended by analysts >> Disclaimer & DisclosureReport an Issue
